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Abstract The tumor necrosis factor (TNF) inducible protein
A20 is a potent inhibitor of nuclear factor-UB (IUB)-mediated
gene expression in response to TNF and several other stimuli.
The C-terminal domain of A20 is characterized by seven zinc
finger structures. Here, we show that a minimum of four zinc
fingers is required to inhibit TNF-induced nuclear factor-UB
(NF-UB) activation to a level that is comparable to that obtained
with the wild-type A20 protein. However, there was no strict
requirement for a particular zinc finger structure, since a mutant
A20 protein containing only the first four zinc fingers was as
potent as a mutant protein containing only the last four zinc
fingers. A similar functional redundancy of the A20 zinc fingers
was also observed for binding of A20 to a number of other
proteins, including two novel NF-UB inhibitory proteins (ABIN-
1, ABIN-2), A20 itself, the anti-apoptotic protein TXBP151, and
a regulatory component of the IUB kinase complex, IKKQ.
Moreover, we demonstrate that complete loss of binding of any
of these proteins correlates with complete loss of A20’s ability to
inhibit TNF-induced NF-UB activation. However, binding of
IKKQ as such is not sufficient for inhibition of NF-UB dependent
gene expression in response to TNF. ß 2001 Federation of
European Biochemical Societies. Published by Elsevier Science
B.V. All rights reserved.
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1. Introduction
A20 was originally identi¢ed as a tumor necrosis factor
(TNF) responsive gene in human endothelial cells [1]. A large
number of other stimuli also induce the expression of the A20
gene. These include the binding of human cytomegalovirus to
unactivated monocytes [2], CD40 ligand [3], integrins [4], in-
terleukin-1 (IL-1) [5], lipopolysaccharide [6], the latent mem-
brane protein 1 of Epstein^Barr virus [7], the human T-cell
leukemia virus type I Tax protein [8], and polyribocytidilic-
polyriboinosinic acid [9]. A20 protects cells from TNF-in-
duced apoptosis as well as necrosis [3,10,11]. It should be
mentioned that an anti-apoptotic activity of A20 cannot be
observed in all cells, suggesting cell-line speci¢c mechanisms.
Interestingly, A20 also strongly inhibits nuclear factor-UB
(NF-UB) dependent gene expression in response to TNF and
several other stimuli [5,12,13]. A20 expression itself is regu-
lated by NF-UB, and is mediated by two adjacent NF-UB-
binding sites in the A20 promoter [7,14]. The latter suggests
that A20 is involved in the negative feedback regulation of
NF-UB activation. A20 de¢cient cells, indeed, fail to terminate
TNF-induced NF-UB activation [15].
We previously identi¢ed a number of A20 associating pro-
teins, including ABIN-1 (A20-binding inhibitor of NF-UB ac-
tivation; previously referred [12] to as ABIN), ABIN-2, A20
itself, and TXBP151 [16]. ABIN-1 and ABIN-2, upon over-
expression, inhibit NF-UB activation induced by both TNF
and IL-1, and have therefore been proposed to be involved
in the NF-UB inhibitory e¡ect of A20 ([12], Van Hu¡el et al.,
manuscript in preparation). TXBP151 has anti-apoptotic
properties, and has been shown to mediate at least partially
the anti-apoptotic e¡ect of A20 [17]. The functional relevance
of A20 oligomerization is not known [18]. Zhang et al. have
shown that A20 also binds inhibitor of NF-UB kinase Q
(IKKQ) [19], which was identi¢ed as a component of the pu-
ri¢ed IKK complex and is essential for NF-UB activation [20].
Finally, A20 also binds to TNF receptor-associated factors
(TRAFs), including TRAF2 and TRAF6 [13,21]. The C-ter-
minal domain of A20 contains seven novel zinc ¢nger motifs
of the type CX2ÿ4CX11CX2C [22] (Fig. 1). All of the A20
interacting proteins, except TRAF2 and TRAF6, interact
with this C-terminal domain of A20 [16]. An A20 zinc ¢nger
was also identi¢ed in the GDP/GTP exchange protein rab5
[23] and the AWP1 (associated with PRK1) protein [24]. In
this study, we examined in detail the role of the seven zinc
¢ngers of A20 in both NF-UB inhibition and in the binding of
A20 associating proteins. We show a functional redundancy
of the seven zinc ¢nger elements and a minimal requirement
of four zinc ¢ngers for full activity. Moreover, we demon-
strate that binding of IKKQ as such is not su⁄cient for inhi-
bition of NF-UB dependent gene expression in response to
TNF.
2. Materials and methods
2.1. Cells and reagents
HEK293T cells (adenovirus-transformed human embryonic kidney
cells, expressing SV40 large T antigen) (a kind gift of Dr. M. Hall,
Department of Biochemistry, University of Birmingham, UK) were
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cultured in Dulbecco’s modi¢ed Eagle’s medium, supplemented with
10% fetal calf serum, 2 mM L-glutamine, 106 U/l streptomycin, 100
mg/ml penicillin and 0.4 mM sodium pyruvate. Recombinant human
TNF was expressed in Escherichia coli and had a speci¢c biological
activity of 2.3U107 IU/mg puri¢ed protein, as determined with the
International Standard (code 88/532) (National Institute for Biologi-
cal Standards and Control, Potters Bar, UK). Protein A on Trisacryl
beads waas obtained from Pierce Chemicals (Rockford, IL, USA).
Anti-FLAG M2 monoclonal antibody was obtained from Sigma (St.
Louis, MO, USA) and a monoclonal anti-E tag, horseradish peroxi-
dase (HRP)-conjugated, antibody was obtained from Amersham
Pharmacia Biotech (Uppsala, Sweden). The polyclonal antibody di-
rected against a C-terminal peptide of TXBP151 has been described
previously [17]. A monoclonal antibody to anti-HA, HRP-conjugated,
was obtained from Roche Molecular Biochemicals ^ Research (Basel,
Switzerland).
2.2. Expression plasmids
The plasmid pNFconluc, containing the luciferase gene under the
control of a minimal promoter, preceded by three NF-UB sites, was a
gift from Dr. A. Israe«l (Institut Pasteur, Paris, France). pUT651, a
L-galactosidase expression plasmid, was obtained from Cayla (Tou-
louse, France). Full-length FLAG-tagged murine A20 and its mutants
were generated by standard PCR methods, and cloned into the eu-
karyotic expression vector pCAGGS [25] by means of XhoI/BglII
digestion. A XhoI restriction site was included in the forward primer
that also incorporated the FLAG epitope sequence in frame with the
N-terminus of A20. The reverse primer contained a BglII restriction
site and the stop codon of the murine A20 cDNA [12]. All constructs
were con¢rmed by entirely sequencing the open reading frame of each
individual mutant construct. The plasmids pCAGGS/ABIN-1 (con-
taining the largest identi¢ed splice variant of ABIN-1), pCAGGS/
TXBP151, and pCAGGS/A20 (E-tagged) have been described previ-
ously [12,17,26]. The plasmid pCAGGS/ABIN-2 will be described
elsewhere (Van Hu¡el et al., manuscript in preparation). The plasmid
pM-IKKQ was kindly provided by Dr. Kuan-Teh Jeang (NIH, Bethes-
da, MD, USA) and has been described [27].
2.3. NF-UB dependent reporter assays
HEK293T cells were seeded at a concentration of 2U105 cells/well
on 6-well (35 mm) plates. Cells were transfected the next day by DNA
calcium phosphate coprecipitation with 0.1 Wg pUT651, 0.1 Wg
pNFconluc, and 0.1 Wg of each of the FLAG-tagged A20 expression
plasmids. The total amount of DNA (1 Wg) was kept constant by
supplementing with the empty vector, pCAGGS. 16^18 h after trans-
fection, cells were seeded in 24-well plates. 24 h later, cells were either
treated with TNF (1000 IU/ml) or left untreated for 6 h, prior to lysis
in luciferase assay lysis bu¡er [26]. The L-galactosidase expression
vector pUT651 was used to normalize transfection e⁄ciencies.
2.4. Coimmunoprecipitation and immunoblotting
HEK293T cells were seeded at a concentration of 1.5U106 on 900
mm plates and transfected with a total of 4 Wg of various constructs.
16^18 h after transfection, the medium was replaced. 36 h after trans-
fection, the cells were harvested, washed twice with cold phosphate-
bu¡ered saline and lysed for 15 min at 4‡C in 1 ml of E1A bu¡er (50
mM HEPES (pH 7.6), 250 mM NaCl, 5 mM EDTA and 0.1% NP-40)
[28]. The samples were centrifuged at 14 000 rpm for 10 min, and 9/10
of the lysate was incubated with 5 Wg of monoclonal anti-FLAG
antibody for 2 h at 4‡C, then mixed with 50 Wl of a 1:1 slurry of
protein A on Trisacryl beads, and incubation was continued for an
additional 2 h. The beads were washed twice with 0.5 ml E1A bu¡er,
twice with 0.5 ml E1B bu¡er, and twice again with 0.5 ml E1A bu¡er.
E1B bu¡er is identical to E1A bu¡er, except for the presence of 1 M
NaCl [28]. Protease inhibitors (100 Wg/ml PMSF, 0.27 trypsin inhib-
itory U/ml aprotinin and 10 Wg/ml leupeptin) and phosphatase inhib-
itors (2 mM Na3VO4, 10 mM NaF, and 26 mM L-glycerophosphate)
were included in both E1A and E1B bu¡er throughout the entire
procedure. In the case of the A20^IKKQ interaction, the beads were
washed at least four times with 0.5 ml of E1A bu¡er, but not with
E1B bu¡er [19]. The remainder of each cell lysate was used for the
detection of the expressed proteins. The immunoprecipitates were
fractionated by sodium dodecyl sulfate^polyacrylamide gel electro-
phoresis (SDS^PAGE), and transferred to nitrocellulose membrane
(SchleicherpSchuell, Dassel, Germany). Western blot analysis was
performed as described previously [21]. The anti-TXBP151 antibody
was used at a 1:2000 dilution, the anti-FLAG antibody at 1 Wg/ml, the
anti-E tag^HRP conjugate at a 1:5000 dilution, and the anti-HA^
HRP conjugate at a 1:3000 dilution. Secondary antibodies were
used at a 1:2000 dilution.
3. Results
It is well established that the C-terminal zinc ¢nger contain-
ing domain of both human and murine A20 is responsible for
the inhibitory e¡ect of A20 on TNF-induced NF-UB activa-
tion [13,21]. To investigate how many, and which zinc ¢ngers
in particular, are required for this activity, we generated a
series of C-terminal deletion mutants of murine A20. Fig.
2A shows the relative expression level of the various A20
mutants, after transient expression in HEK293T. To analyze
the inhibitory potential of each mutant on TNF-induced NF-
UB activation, HEK293T cells were cotransfected with the
corresponding expression plasmid, a NF-UB dependent lucif-
erase reporter plasmid and a L-galactosidase expression plas-
mid. 36 h after transfection, cells were either untreated or
stimulated with TNF for 6 h. Subsequently, cell lysates were
prepared and analyzed for NF-UB dependent reporter gene
expression. As shown in Fig. 2B, deletion of the two C-termi-
nal zinc ¢ngers (A20[1^699]) did not a¡ect the potential of
A20 as an inhibitor of TNF-induced NF-UB activation. Dele-
tion of the three C-terminal zinc ¢ngers (A20[1^640]) reduced
the activity of A20 slightly, while a further deletion of one
more zinc ¢ngers (A20[1^590]) drastically a¡ected A20’s func-
tion. As shown previously, the N-terminal domain of A20
(A20[1^367]) was ine¡ective as an inhibitor of TNF-induced
NF-UB activation [13,21]. These results show that a minimum
of three zinc ¢ngers is su⁄cient, but that a total of four zinc
¢ngers is most e¡ective for A20’s function as an inhibitor of
TNF-induced NF-UB activation.
Since the zinc ¢ngers and the surrounding sequences are
conserved in both human and murine A20 [22] (Fig. 1), we
wondered if di¡erent zinc ¢ngers could substitute for one
another. To test this hypothesis, we created a series of internal
Fig. 1. Schematic representation of murine A20 and the localization of the seven zinc ¢ngers (Zf) in its C-terminal domain (top). Amino acid
sequence alignment of the seven zinc ¢nger elements by ClustalW [29] analysis (bottom). The cysteine residues of the zinc ¢nger structures are
indicated in bold.
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deletions in the C-terminal domain of murine A20. As shown
in Fig. 2C, deletion of none of the three N-terminal zinc
¢ngers (A20[del 386^428], A20[del 386^468], A20[del 386^
504], and A20[del 505^590]) signi¢cantly a¡ected the function
of A20. Moreover, a combination of the last four zinc ¢ngers
(A20[591^775]) was almost as e¡ective as the wild-type A20
protein. These results further demonstrate that a total of four
A20 zinc ¢ngers is su⁄cient to inhibit TNF-induced NF-UB
activation, and that the intervening non-zinc ¢nger containing
elements are not essential. Moreover, two regions in the C-
terminal domain of A20, corresponding to either the ¢rst four
zinc ¢ngers or the last four zinc ¢ngers, can mediate its NF-
UB inhibitory potential. Because all of the above mentioned
A20 mutants that inhibited TNF-induced NF-UB activation
still contained the fourth zinc ¢nger of A20, it was still pos-
sible that this speci¢c zinc ¢nger was responsible for NF-UB
inhibition. However, a mutant in which zinc ¢ngers 4 and 5
were deleted, thereby fusing zinc ¢nger 3 with zinc ¢nger 6
(A20[del 547^699]), was as potent as the wild-type murine A20
to inhibit TNF-induced NF-UB activation. This ruled out the
Fig. 3. Binding of A20 mutants with ABIN-1, ABIN-2, A20,
TXBP151 and IKKQ. FLAG-tagged A20 and its deletion mutants,
as indicated, were cotransfected with either E-tagged ABIN-1,
E-tagged ABIN-2, TXBP151, E-tagged A20, or HA-tagged IKKQ
into HEK293T cells. 36 h after transfection, cell extracts were pre-
pared and A20 and A20 mutants were immunoprecipitated with
anti-FLAG antibody M2. Coimmunoprecipitating proteins were re-
vealed by SDS^PAGE and immunoblotting. For each coimmuno-
precipitating protein, the upper panel shows the amounts of copreci-
pitating protein (IP), while the lower panel shows the expression of
each of the coprecipitating proteins in total lysates (TL). Similarly,
equal expression of the various A20 mutant proteins was con¢rmed
by immunoblotting total cell extracts with anti-FLAG antibody
(data not shown).
Fig. 2. E¡ect of A20 mutants on TNF-induced NF-UB activation.
HEK293T cells were transiently cotransfected with the indicated
FLAG-tagged mutant A20 expression plasmids, a NF-UB dependent
luciferase reporter plasmid, and a L-galactosidase expression plas-
mid. 36 h after transfection, cells were analyzed for A20 expression
by SDS^PAGE and immunoblotting (A). The e¡ect of C-terminal
(B) or internal (C) deletion mutants of A20 on NF-UB dependent
gene expression in response to 6 h TNF treatment was measured as
described in Section 2. Values correspond to means þ S.E.M. of
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possibility that zinc ¢nger four was essential for A20’s func-
tion. Overall, we conclude that there is redundancy of the zinc
¢ngers of A20 for inhibition of NF-UB activation.
We next examined if a similar redundancy exists for binding
of A20 to several of the A20 associating proteins, and whether
loss of inhibition of TNF-induced NF-UB activation by dele-
tion of speci¢c zinc ¢ngers is associated with loss of A20’s
capacity to bind speci¢c proteins. For this purpose, we tran-
siently transfected the A20 mutant expression plasmids (which
all contained an N-terminal FLAG tag) individually with ei-
ther an expression plasmid encoding ABIN-1, ABIN-2, or
TXBP151. All of these proteins have been shown previously
to bind to the C-terminal zinc ¢nger containing domain of
A20 ([12,17], Van Hu¡el et al., manuscript in preparation).
36 h after transfection, cell lysates were prepared and an
antibody directed against the FLAG epitope was used to
immunoprecipitate the various A20 proteins. Coimmunopre-
cipitating proteins were revealed by SDS^PAGE and immu-
noblotting. Deletion of the last four zinc ¢ngers in A20
(A20[1^590]) signi¢cantly reduced its association with
ABIN-1, ABIN-2, and TXBP151, but a mutant having only
the last four zinc ¢ngers of A20 (A20[591^775]) still retained
its ability to bind these three proteins (Fig. 3). These results
demonstrate that the A20 zinc ¢ngers also have a redundant
role in the binding to other proteins. Although comparison of
the e¡ect of the di¡erent A20 mutants on NF-UB activation
and their ability to bind to other proteins does not allow us to
make any conclusions about the role of these proteins in NF-
UB inhibition, our results clearly demonstrate that a correla-
tion exists between the loss of their binding and A20’s ability
to inhibit NF-UB activation.
To analyze the role of speci¢c zinc ¢ngers in A20 oligome-
rization, we cotransfected FLAG-tagged mutant A20 expres-
sion plasmids with an E-tagged A20 expression plasmid. Fig.
3 shows that deleting the ¢rst three (A20[547^775]) or the last
four zinc ¢ngers (A20[1^590]) considerably compromised
A20’s ability to inhibit TNF-induced NF-UB activation, we
conclude that A20 oligomerization as such is not su⁄cient
for NF-UB inhibition.
Finally, we examined the interaction of A20 with IKKQ.
Zhang et al. have demonstrated that both the N-terminal
and C-terminal domains of A20 are involved in binding to
IKKQ [19]. However, we were unable to show any interaction
of IKKQ with the N-terminal domain of A20 (which lacks any
zinc ¢nger) (Fig. 3). Extending the N-terminal domain with as
little as one zinc ¢nger (A20[1^468]) was su⁄cient to restore
IKKQ-binding almost completely. Interestingly, the latter mu-
tant had no NF-UB inhibitory activity, suggesting that binding
of A20 to IKKQ as such is not su⁄cient for its NF-UB inhib-
itory potential.
4. Discussion
In this study, we have investigated by deletional analysis the
role of the seven zinc ¢ngers of A20, for its NF-UB inhibitory
potential and capacity to bind a number of proteins. Remark-
ably, either the ¢rst three or last four zinc ¢ngers are su⁄cient
for NF-UB inhibition, indicating that two regions in the C-
terminal domain of A20 can mediate its NF-UB inhibitory
e¡ect. In contrast to our study, Natoli et al. have demon-
strated that the last zinc ¢nger of human A20 is absolutely
required for inhibition of TNF-induced NF-UB activation
[30]. However, we show that deletion of zinc ¢ngers 6 and 7
does not a¡ect the NF-UB inhibitory potential of murine A20.
The reason for these controversial results is still unclear, but
might be due to di¡erences in expression levels and the cells
used in both studies (HEK293T versus HeLa cells). Natoli et
al. also demonstrated that a four times fusion of zinc ¢nger 7
of human A20 is su⁄cient to inhibit TNF-induced NF-UB
activation [30]. Together with our ¢nding that the last four
zinc ¢ngers of murine A20 are su⁄cient for NF-UB inhibition,
these results further demonstrate the minimal requirement for
a particular number of zinc ¢ngers and their functional redun-
dancy in inhibiting TNF-induced NF-UB activation.
A similar redundancy of the zinc ¢ngers could be demon-
strated for A20’s ability to bind to ABIN-1, ABIN-2,
TXBP151, IKKQ, and A20 itself. All these proteins are able
to bind a mutant A20, lacking the last four zinc ¢ngers, as
well as to a mutant consisting of only the last four zinc ¢n-
gers, albeit with di¡erent a⁄nity. This suggests that at least
two di¡erent proteins might bind simultaneously to the C-
terminal domain of a single A20 protein. Whether A20 oligo-
merization is involved in its inhibition of NF-UB activation is
still unclear. However deletion of the last four zinc ¢ngers
strongly reduced the activity of A20, whereas its oligomeriza-
tion was una¡ected. Therefore, it is unlikely that A20 oligo-
merization as such is su⁄cient for NF-UB inhibition. Simi-
larly, A20’s potential to bind IKKQ does not correlate with
inhibition of TNF-induced NF-UB activation. In this case, a
mutant A20 protein containing only the N-terminal domain
and the ¢rst zinc ¢nger was still able to bind IKKQ, but was
unable to prevent NF-UB activation. These results clearly in-
dicate that binding of A20 to the IKK complex might be
involved, but is certainly not su⁄cient for NF-UB inhibition.
In conclusion, we have provided evidence that the zinc
¢ngers of A20 have a redundant role in the inhibition of
TNF-induced NF-UB activation, as well as in the binding of
several proteins. The latter also suggests that the C-terminal
domain of A20 might have the potential to simultaneously
bind at least two di¡erent proteins, and act as a sca¡old
protein.
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